CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Read MoreSafety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV₁ <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Mechanism of Action & Delivery

CAYSTON is the only FDA-approved MONOBACTAM inhaled antibiotic to treat cystic fibrosis (CF) patients with PSEUDOMONAS AERUGINOSA (Pa)

Activity in vitro against Pa, a gram-negative bacteria

The chemical structure confers specificity for aerobic gram-negative bacteria and enhances beta-lactamase stability
Binds to penicillin-binding proteins of susceptible bacteria
Leads to inhibition of bacterial cell wall synthesis and death of the cell
Activity not decreased in the presence of CF lung secretions

Cell wall maintenance of Pa

Inhibition of Pa cell wall synthesis icon

Pa cell wall layer

Connections between cell wall layers are made by penicillin-binding proteins, providing structural integrity

Penicillin-binding protein

CAYSTON binds to penicillin-binding protein of Pa

CAYSTON

Inhibition of Pa cell wall synthesis and cell death

Delivery

Inhaled antibiotic delivered directly to the airways

The airways of the lungs are the site of Pa infection
CAYSTON is aztreonam that has been reformulated for inhalation with the amino acid lysine

CF airway infected with Pa

Pseudomonas aeruginosa infected airway image

See the Full Prescribing Information to learn more

"I know now that it is very important to treat Pa. My doctor told me that if left untreated, my breathing symptoms could get worse and I may see a further decline in my lung function."

Read how Emily, a real patient treated with CAYSTON, manages her Pa.

Remind patients to enroll at cayston.com/my-cayston-community

Learn about the Systemic Exposure and Microbiology of CAYSTON

Tap for Important Safety Information

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

Continued below

Please read the following Important Safety Information before your video begins.

Important Safety Information and Indication

Contraindications

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV₁ <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Warnings and Precautions

Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.
Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV₁) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.
Decreases in FEV₁ After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV₁ during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV₁ declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV₁ measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV₁ are caused by a pulmonary exacerbation.
Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.

Indication

Please click here to see full Prescribing Information.

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

ALLY, CAYSTON, the CAYSTON logo, CAYSTON ACCESS PROGRAM, the CAYSTON ACCESS PROGRAM logo, GILEAD, the GILEAD logo, and MY CAYSTON COMMUNITY are trademarks of Gilead Sciences, Inc. ALTERA is a registered trademark of PARI Pharma GmbH. All other trademarks referenced herein are the property of their respective owners.